89Zr-bevacizumab PET Scan in Patients With Relapsing Multiple Myeloma

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to see whether 89Zr-bevacizumab PET scanning is feasible in relapsing multiple myeloma patients.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Medical Center Groningen
• Treatments: 89Zr-bevacizumab; Bevacizumab

Criteria

Inclusion Criteria:

Patients with relapsing multiple myeloma according to international defined guidelines:

Relapse after having achieved complete remission:

1. Reappearance of paraprotein

2. More than 5% plasma cells in bone marrow.

3. New lytic lesions or progression of old lesions.

4. New hypercalcaeamia.

Relapse after having achieved partial remission

1. Increases of paraprotein with more than 25%

2. Increase of urine paraprotein with more than 25%

3. Increase of plasma cells in bone marrow with 10%

4. New lytic lesions or progression of old lesions

5. New hypercalcaemia -

Exclusion Criteria:

Radiotherapy in the last 3 months.

• Ineligible to lay supine during the PET scan.

• Age ≤18 years.

• Pregnancy.

• Claustrophobia

• Severe kidney dysfunction; serum-creatinine ≥250 µM